Mecasermin

SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

Key facts

Mecasermin is a drug catalogued in DrugCentral. It was first approved by the FDA in 2005. DrugCentral lists 2 molecular targets, including IGF1R and INSR. Recorded indications include Laron-type isolated somatotropin defect.

• Molecular targets: IGF1R and INSR (2 listed in DrugCentral).
• Indications: Laron-type isolated somatotropin defect.
• ATC code: H01AC03 (Somatropin and somatropin agonists).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Laron-type isolated somatotropin defect

Mechanism & targets

Molecular targets (2)

Target	Gene	Action	Activity
Insulin-like growth factor 1 receptor	IGF1R	agonist	IC50 8.31
Insulin receptor	INSR	unknown	IC50 5.85

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2007-03-08	EMA	—	—
2005-08-30	FDA	—	IPSEN INC	Yes

ATC classification

ATC code	Therapeutic hierarchy
H01AC03	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS › PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES › ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES › Somatropin and somatropin agonists

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: IGF1
• FDA label: GH1, IGF1
• HCSC label: GH1, GHR, IGF1

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Tonsillar hypertrophy	208.8
Hypoglycaemia	141.8
Product dose omission issue	83.9
Adenoidal hypertrophy	77.2
Papilloedema	53.6
Snoring	52.5
Injection site pain	49.3
Injection site urticaria	46.0
Blood glucose decreased	45.6
Idiopathic intracranial hypertension	44.2
Off label use	41.1

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: —
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Mecasermin used for?

DrugCentral lists the following indications for Mecasermin: Laron-type isolated somatotropin defect.

How does Mecasermin work?

Its molecular targets in DrugCentral include IGF1R (agonist) and INSR.

When was Mecasermin first approved?

Mecasermin was first approved by the FDA in 2005.

Sources

• DrugCentral drug card 5009 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201716 — compound record and bioactivity
• DrugBank DB01277 — drug record
• FDA UNII 7GR9I2683O — substance identity
• DailyMed: FDA labels for Mecasermin — current prescribing information (label search)
• UniProt P08069 (IGF1R) — target protein
• UniProt P06213 (INSR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.